New Formulation of Asthma Inhalant Pulled Off Market
- Share via
WASHINGTON — A new version of a widely used asthma drug is being pulled off the market because of increased reports of such side effects as coughing and choking, the Food and Drug Administration announced Friday.
Boehringer Ingelheim of Ridgefield, Conn., has agreed to stop marketing its new version of a prescription asthma inhalant sold under the brand name Aluprent, the FDA said.
Sandoz Pharmaceuticals of East Hanover, N.J., has distributed the same drug under the brand name Metaprel to the Veterans Administration. It is also withdrawing all lots of the new formulation.
More From the Los Angeles Times
Podcasts
The latest effort is coming from the L.A. County Board of Supervisors. They just announced a $3 million program in conjunction with some nonprofits groups to test and clean the soil at homes still standing in the areas impacted by the Eaton Fire.
California once bet big on offshore wind to help power its clean-energy future, but the Trump administration is now paying developers billions to walk away from their projects. As California’s remaining offshore-wind leases hang in the balance, the state is fighting back in court.
The Hillside Strangler murders terrorized Los Angeles in the late 1970s. The killers were a pair of sadistic cousins. One confessed. The other was set to stand trial—until L.A. prosecutors flinched.
